Why Kiniksa Pharmaceuticals International (KNSA) is back on investors’ radar

Recent commentary around Kiniksa Pharmaceuticals International (KNSA) has focused on strong earnings, faster sales trends across its portfolio, and increasingly positive analyst views, drawing fresh attention to the stock.

At a share price of $43.92, Kiniksa has seen a 90 day share price return of 13.96%, while its one year total shareholder return of 132.63% and three year total shareholder return of about 3x suggest strong momentum that has built over time rather than faded.

If Kiniksa’s run has caught your eye, this could be a useful moment to broaden your watchlist with other healthcare stocks that might fit a similar thesis.

With earnings growth running ahead of sales, a reported intrinsic value gap of about 71%, and a roughly 25% discount to analyst targets, you have to ask: is Kiniksa still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 20.1% Undervalued

With the most followed narrative pointing to a fair value of $55 against a last close of $43.92, the gap hinges heavily on how durable ARCALYST and the pipeline prove to be.

Significant expansion opportunities for ARCALYST remain, as market penetration into the recurrent pericarditis population is still only 15%, with a large additional segment (first recurrence patients) representing another untapped 26,000 patients. This is likely to continue to accelerate topline revenue growth as adoption widens across a growing addressable market due to population aging and rising prevalence of autoimmune/inflammatory disorders.

Curious what kind of revenue ramp and margin lift underpin that fair value gap? The narrative leans on a sharp earnings curve and a richer future profit multiple. Want to see exactly how those assumptions stack up over time?

Result: Fair Value of $55 (UNDERVALUED)

However, the story could shift quickly if ARCALYST uptake slows, or if new competitors and pricing pressure start to bite into that single key revenue engine.

Another View: Earnings Multiple Sends a Different Signal

Here is the tension. While the most popular narrative leans on a fair value of $55 and a wide intrinsic value gap, Kiniksa currently trades on a P/E of 92.7x versus a peer average of 48.3x and a fair ratio of 23.8x, which points to a very rich earnings multiple. Is the market already front loading a lot of that future earnings story?

Build Your Own Kiniksa Pharmaceuticals International Narrative

If you look at these numbers and come to a different conclusion, or simply prefer to test your own assumptions, you can build a complete narrative in just a few minutes with Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Kiniksa Pharmaceuticals International.

Looking for more investment ideas?

If Kiniksa is already on your radar, do not stop there. Use the Simply Wall Street Screener to quickly spot other stocks that fit the kind of opportunities you care about.

• Spot potential mispriced opportunities by checking out these 887 undervalued stocks based on cash flows that may offer stronger cash flow support for their current prices.
• Tap into fast moving themes with these 18 cryptocurrency and blockchain stocks tied to blockchain and digital asset adoption across different business models.
• Build a cash flow focused watchlist using these 12 dividend stocks with yields > 3% that currently offer yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.